Novel anticonvulsant drugs

Pharmacology and Therapeutics

Volumn 113, Issue 1, 2007, Pages 165-183

  Stefan, H ^a   Feuerstein, T J ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anticonvulsant drugs; Efficacy; Mechanisms of action; Pharmacology; Safety

Indexed keywords

ANTACID AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; DIGOXIN; ERYTHROMYCIN; ETHINYLESTRADIOL; ETIRACETAM; FELODIPINE; GABAPENTIN; LAMOTRIGINE; LEVONORGESTREL; METFORMIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENPROCOUMON; PHENYTOIN; PREGABALIN; PRIMIDONE; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VIGABATRIN; WARFARIN; ZONISAMIDE;

AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANOREXIA; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; BLEPHAROSPASM; CLEFT LIP; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONFUSION; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; ENZYME INDUCTION; ENZYME INHIBITION; EPILEPSY; FATIGUE; FETUS MALFORMATION; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INSOMNIA; KIDNEY DISEASE; LENNOX GASTAUT SYNDROME; LEUKOPENIA; LIVER DISEASE; MOTOR DYSFUNCTION; NAUSEA; NERVOUSNESS; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; SOMNOLENCE; SPEECH DISORDER; THROMBOCYTOPENIA; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

AMINES; ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSY; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; ISOXAZOLES; NIPECOTIC ACIDS; PIRACETAM; TREATMENT OUTCOME; TRIAZINES;

EID: 33845914088     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.07.005     Document Type: Review

References (177)

1. Adler C.H. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 20 (1997) 148-151
2. Averbuch-Heller L., Tusa R.J., Fuhry L., Rottach K.G., Ganser G.L., Heide W., et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 41 (1997) 818-825
3. Balslev T., Uldall P., and Buchholt J. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. Eur J Paediatr Neurol 4 (2000) 169-170
4. Baruzzi A., Albani F., and Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35 3 (1994) 14-19
5. Baumgartner, C. H., Stefan, H. (2006). Epilepsien in Aktuelle Therapie in der Neurologie-Kompendium für die Fort-und Weiterbildung, Hrsg. Stefan, H., Mamoli, B., ECOMED Verlag, Landshut, 7. Ergänzungslieferung.
6. Benes J., Parada A., Figueiredo A.A., Alves P.C., Freitas A.P., Learmonth D.A., et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 4 14 (1999) 2582-2587
7. Ben-Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
8. Betts T., Waegemans T., and Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9 (2000) 80-87
9. Bill P.A., Vigonius U., Pohlmann H., Guerreiro C.A., Kochen S., Saffer D., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27 (1997) 195-204
10. Birnstiel S., Wulfert E., and Beck S.G. Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 611-618
11. Biton V., Montouris G.D., Ritter F., Riviello J.J., Reife R., Lim P., et al. A randopmized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 53 (1999) 1162
12. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., Mikkelsen J.D., and Blackburn-Munro R.E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 11 1 (2005) 1-20
13. Blum D.E. New drugs for persons with epilepsy. Adv Neurol 76 (1998) 57-87
14. Blum R.A., Comstock T.J., Sica D.A., Schultz R.W., Keller E., Reetze P., et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56 (1994) 154-159
15. Borowicz K.K., Swiader M., Wielosz M., and Czuczwar S.J. Influence of the combined treatment of LY 300164 (an AMPA/kainate receptor antagonist) with adenosine receptor agonists on the electroconvulsive threshold in mice. Eur Neuropsychopharmacol 14 5 (2004) 407-412
16. Brodie M.J., Overstall P.W., Giorgi L., and The UK Lamotrigine Elderly Study Group. Multicenter, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 37 (1999) 18-87
17. Brodie M.J., Chadwick D.W., Anhut H., Otte A., and for the Gabapentin-Study group 945-212. Gabapentin Monotherapie versus Lamotrigin-Monotherapie: ein doppelblinder Vergleich bei neu diagnostizierter Epilepsie. Epilepsia 43 (2002) 993-1000
18. Brodie M.J., Duncan R., Vespignani H., Solyom A., Bitensky V., and Lucas K. Dosisabhängige Sicherheit und Wirksamkeit von zonisamid: Eine randomisierte, doppelblinde, plazebokontrollierte Studie an Patienten mit refraktären fokalen Anfällen. Epilepsia 46 1 (2005) 31-41
19. Bruni J. Gabapentin. Can J Neurol Sci 23 (1996) 10-12
20. Calbrese J.R. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 61 (2000) 841-850
21. Cereghino J.J., Biton V., Abou K.B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
22. Chadwick D., Leiderman D.B., Sauermann W., Alexander J., and Garofalo E. Gabapentin in generalized seizures. Epilepsy Res 25 (1996) 191-197
23. Cramer J.A., Fisher R., Ben-Menachem E., French J., and Mattson R. New antiepileptic drugs: comparison of key trials. Epilepsia 40 (1999) 590-600
24. Cramer J.A., Arrigo C., Van-Hammee G., Gauer L.J., and Cereghino J.J. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 41 (2000) 868-874
25. Cramer J.A., Ben-Menachem E., and French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 47 (2001) 17-25
26. Crumrine R.C., Bergstrand K., Cooper A.T., Faison W.L., and Cooper B.R. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 28 (1997) 2230-2236
27. Cunha R.A., Coelho J.E., Costenla A.R., Lopes L.V., Parada A., de Mendonca A., et al. Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. Pharmacol Toxicol 90 4 (2002) 208-213
28. Dam M., Ekberg R., Loyning Y., Waltimo O., and Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3 (1989) 70-76
29. Doheny H.C., Ratnaraj N., Whittington M.A., Jefferys J.G., and Patsalos P.N. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 34 (1999) 161-168
30. Edwards K.R., Sackellares J.Ch., Vuong A., Hammer A.E., and Barrett P.S. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2 (2001) 28-36
31. Errante L.D., and Petroff O.A. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 12 5 (2003) 300-306
32. Errington A.C., Stohr T., and Lees G. Voltage gated ion channels: targets for anticonvulsant drugs. Curr Top Med Chem 5 1 (2005) 15-30
33. Faught E., Ayala R., and Montorious G.G. Randomized controlled trial of zonisamide for the treatment of refractory partial onset seizures. Neurology 7 (2001) 1777-1779
34. ATP channels. Naunyn Schmiedebergs Arch Pharmacol 363 (2001) 537-542
35. French J.A., Kugler A.R., Robbins J.L., and Knapp L.E. Pregabalin adjunctive therapy in patients with partial seizures. Neurology 60 10 (2003) 1631-1637
36. French J.A., Kanner A.S.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., et al. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 5 (2004) 401-409
37. French J.A., Kanner A.S.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 5 (2004) 410-423
38. Gatti G., Bonomi I., Jannuzzi G., and Perucca E. The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des 6 (2000) 839-860
39. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 22 (2000) 75-80
40. Gidal B.E., Maly M.M., Nemire R.E., and Haley K. Weight gain and gabapentin therapy [letter]. Ann Pharmacother 29 (1995) 1048-1054
41. Gidal B.E., Maly M.M., Budde J., Lensmeyer G.L., Pitterle M.E., and Jones J.C. Effect of a high-protein meal on gabapentin pharmacokinetics. Epilepsy Res 23 (1996) 71-76
42. Gironell A., Kulisevsky J., Barbanoj M., Lopez V.D., Hernandez G., and Pascual S.B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 56 (1999) 475-480
43. Goldlust A., Su T.Z., Welty D.F., Taylor C.P., and Oxender D.L. Effects of anticonvulsivant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res 22 (1995) 1-11
44. Grant R., and Shorvon S.D. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 42 (2000) 89-95
45. Gryder D.S., and Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23 18 (2003) 7069-7074
46. Gustavson L.E., Sommerville K.W., Boellner S.W., Witt G.F., Guenther H.J., and Granneman G.R. Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Am J Ther 5 (1998) 73-79
47. Hammondet E.J., Perchalski R.J., Wilder B.J., and McLean J.R. Neuropharmacology of zonisamide, a new antiepileptic drug. Gen Pharmacol 18 (1987) 303-307
48. Hanaya R., Sasa M., Ujihara H., Ishihara K., Serikawa T., Iida K., et al. Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res 780 (1998) 274-282
49. Herzog A., Drislane F.W., and Schomer D.I. Differential antiepileptic drug effects on sex hormones and reproductive hormones: a comparison between lamotrigne and enzyme-inducing antiepileptic drugs. Epilepsia 44 9 (2003) 107-115
50. Hofmann F., Lacinova L., and Klugbauer N. Voltage depedent calcium channels: from structure to function. Rev Physiol Biochem Pharmacol 139 (1999) 33-87
51. Holden K.R., and Titus M.O. The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study. Pediatr Neurol 21 (1999) 728-730
52. Honmou O., Kocsis J.D., and Richerson G.B. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res 20 (1995) 193-202
53. Honmou O., Oyelese A.A., and Kocsis J.D. The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 692 (1995) 273-277
54. Hovinga C.A. Novel anticonvulsant medications in development. Expert Opin Investig Drugs 110 (2002) 1387-1406
55. Hovinga C.A. SPM-927 (Schwarz Pharma). IDrugs 6 5 (2003) 479-485
56. Isojaervi J.I.T., Pakarinen A.J., Rautio A., Pelkonen O., and Myllylae V.V. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 47 5 (1995) 462-464
57. Johannessen A.C., and Nielsen O.A. Hyponatremia induced by oxcarbazepine. Epilepsy Res 1 (1987) 155-156
58. Kilpatrick E.S., Forrest G., and Brodie M.J. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 37 (1996) 534-538
59. Kiura Y., Hanaya R., Serikawa T., Kurisu K., Sakai N., and Sasa M. Involvement of Ca(2+) channels in abnormal excitability of hippocampal CA3 pyramidal cells in noda epileptic rats. J Pharmacol Sci 91 2 (2003) 137-144
60. Klitgaard H. Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol Scand Suppl 181 (2005) 68-72
61. Klosterskov J.P., Saano V., Haring P., Svenstrup B., and Menge G.P. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 33 (1992) 1149-1152
62. Klugbauer N., Marais E., and Hofmann F. Clacium channel alpha2delta subunits:differntial expression, function, and drug binding. J Bioenerg Biomembr 35 6 (2003) 639-647
63. Kocsis J.D., and Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett 169 (1994) 181-184
64. Komatsu M., Okamura Y., and Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences 21 (1995) 23-29
65. Kothare S.V., Pollack P., Kulberg A.G., and Ravin P.D. Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus. Pediatr Neurol 22 (2000) 68-71
66. Kramer G., Tettenborn B., Klosterskov J.P., Menge G.P., and Stoll K.D. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 33 (1992) 1145-1148
67. Labiner D.M. DP-VPA D-Pharm. Curr Opin Investig Drugs 3 6 (2002) 921-923
68. Laird M.A., and Gidal B.E. Use of gabapentin in the treatment of neuropathic pain. Ann Pharmacother 34 (2000) 802-807
69. Lamotrigine pregnanacy registry, January 2006, GlaxoSmithKline.
70. Larkin J.G., McKee P.J., Forrest G., Beastall G.H., Park B.K., Lowrie J.I., et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 31 (1991) 65-71
71. Lieth E., LaNoue K.F., Berkich D.A., Xu B., Ratz M., Taylor C., et al. Nitrogen shuttling between neurons and glial cells during glutamate synthesis. J Neurochem 76 (2001) 1712-1723
72. Lingamaneni R., and Hemmings Jr. H.C. Effects of anticonvulsants on veratridine and KCL-evoked gluitamate release from rat cortical synaptosomes. Neurosciences 276 (1999) 127-130
73. Loffe V., Kalendarev T., Rubinstein I., and Zupkovitz G. Reverse phase HPLC for polar lipids. Simple and selective HPLC procedures for analysis of phospholipid-based derivatives of valproic acid and various non-steroidal anti-inflammatory drugs. J Pharm Biomed Anal 30 3 (2002) 391-403
74. Lofton A.L., and Klein-Schwartz W. Evaluation of toxicity of topiramate exposures reported to poison centers. Hum Exp Toxicol 24 11 (2005) 591-595
75. Loiseau P. Review of controlled trials of gabitril (tiagabine): a clinician's viewpoint. Epilepsia 40 9 (1999) 14-19
76. Löscher W., and Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol 391 (2000) 251-254
77. Löscher W., and Schmidt D. New horizons in the development of antiepileptic drugs II: the search for new targets. Epilepsy Res 60 (2004) 77-159
78. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PAS 26 101 (2004) 9861-9866
79. MacDonald R.L. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Zonisamide - Mechanisms of Action in Antiepileptic Drugs. 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia Section XVII/91
80. MacDonald, R.L., Meldrum, B.S., (1995). Principles of antiepileptic drug action in antiepileptic drugs for sedition edited by R.H. Levy, R.H. Mattson and B.S. Meldrum, Raven Press Ltd. New York p 61-77 and M.A. Rogawsky. Principals of antiepileptic drug action in antiepileptic drugs. Eds. Rene H. Levy, Richard Mattson, B.S. Meldrum, Emilio Perucca, p. 8.
81. Malawska B., and Kulig K. Brivaracetam UCB. Curr Opin Investig Drugs 6 7 (2005) 740-774
82. Malek R., Borowicz K.K., Kimber-Trojnar Z., Sobieszek G., Piskorska B., and Czuczwar S.J. Remacemide - a novel potential antiepileptic drug. Pol J Pharmacol 5 5 (2003) 691-698
83. 2δ subunits: structure and gabapentin binding. Mol Pharmacol 59 (2001) 1243-1248
84. Margineanu D.G., and Klitgaard H. Can gap-junction blockade preferentially inhibit neuronal hypersynchron excitability?. Neuropharmacology 41 3 (2001) 377-383
85. Martin R., Kuzniecky R., and Ho S. Cognitive effects of topiramate, gabapentine and lamotrigine in healthy young adults. Neurology 52 2 (1999) 321-327
86. Marzo A., Dal Bo L., Monti N.C., Crivelli F., Ismaili S., Caccia C., et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 50 1 (2004) 77-85
87. Masson J., Sag C., and Hamon M. Neurotransmitter transporters in the central nervous system. Coll Rev 51 (1999) 439-464
88. Matsumoto H., and Marsan C. Cortical cellelular phenomena in experimental epilepsy: interictal manifestation. Exp Neurol 9 (1964) 286-304
89. Mazarati A.M., Sofia R.D., and Wasterlain C.G. Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus. Seizure 7 (2002) 423-430
90. McKee P.J., Blacklaw J., Forrest G., Gillham R.A., Walker S.M., Connelly D., et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, blind sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 37 (1994) 27-32
91. McLean M.J. Gabapentin in the management of convulsive disorders. Epilepsia 40 6 (1999) 39-50
92. Meador K.J., Loring D.W., Ray P.G., Murro A.M., King D.W., Perrine K.R., et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 56 (2001) 177-1182
93. Meldrum B.S., and Chapman A.G. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 40 9 (1999) 2-6
94. Messenheimer J.A., and Guberman A.H. Rash with lamotrigine: dosing guidelines [letter]. Epilepsia 41 (2000) 488
95. Miles R., and Wong R.K.S. Single neurons can initiate synchronized population discharge in the hippocampus. Nature 306 (1998) 371-373
96. Miles M.V., Tang P.H., Ryan M.A., Grim S.A., Fakhoury T.A., Strawsburg R.H., et al. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbazepine (MHD). Ther Drug Monit 26 3 (2004) 300-304
97. Nicolas J.M., Collart P., Gerin B., Mather G., Trager W., Levy R., et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 27 (1999) 250-254
98. Okada M., Hirano T., and Kawata Y. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 34 (1999) 187-197
99. Pack A.M., Olarte L.S., and Morell M.J. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 4 (2003) 169-174
100. Parker R.J., Hartman N.R., Roecklein B.A., Mortko H., Kupferberg H.J., Stables J., et al. Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by Postmitochondrial suspensions. Chem Res Toxicol 18 12 (2005) 1842-1848
101. Parri H.R., and Crunelli V. Sodium current in rat and cat salamo cortical neurons: role of non-inactivating component in tonic and burst firing. J Neurosci 18 (1998) 854-867
102. Patsalos P.N. Pharmacokinetic profile of Levetiracetam: Toward ideal characteristics. Pharmacol Ther 85 2 (2000) 77-85
103. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 37 2 (1996) 8-13
104. Perucca E., and Kupferberg H.J. In: Levy R.H., Mattson R., Meldrum B.S., and Perucca E. (Eds). Antiepileptic drugs. 5th ed. (2004), William and Wilkins, Lippincott 913-916
105. Petroff O.A., Rothman D.L., Behar K.L., Lamoureux D., and Mattson R.H. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39 1 (1996) 95-99
106. Philippi M., Vyklicky L.M., Kuffler D.P., and Orkand R.K. Serotonin- and proton-induced and modified ionic currents in frog sensory neurons. J Neurosci Res 40 3 (1995) 387-395
107. Pisani F., Oteri G., Russo M.F., Di-Perri R., Perucca E., and Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40 (1999) 1141-1146
108. Pisani A., Bonsi P., Martella G., De-Persis C., Costa C., Pisano F., et al. Intracellular calcium increase in epileptiform acticity: modulation by levetiracetam and lamotrigine. Epilepsia 45 7 (2004) 719-728
109. Poisson M., Huguet F., Savattier A., Bakri-Logeais F., and Narcisse G. A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung 34 2 (1984) 199-204
110. Poolos N.P., Migliore M., and Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 5 8 (2002) 767-774
111. Poulain P., and Margineanu D.G. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacology 42 3 (2002) 346-352
112. Poulsen C.F., Simeone T.A., Maar T.E., Smith-Swintosky V., White H.S., and Schousboe A. Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem Res 29 1 (2004) 275-282
113. Ragstale D.S., and Acoli M. Soldium as molecular targets for antiepileptic drugs. Brain Res Rev 26 (1998) 16-18
114. Ramael S., Doust A., Otoul C., Toublanc N., Trenaru M., Lu Z., et al. Levetricaetam intravenous infusion: A randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 47 7 (2006) 1128-1135
115. Rambeck B., and Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25 (1993) 433-448
116. Rambeck B., Kurlemann G., Stodieck S.R., May T.W., and Jurgens U. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 51 (1997) 481-484
117. Ramsay R.E., and Pryor F. Epilepsy in the elderly. Neurology 55 1 (2000) 9-14
118. Rao M.L., Clarenbach P., Vahlensieck M., and Kratschmar S. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm 73 (1988) 129-134
119. Reddy D.S. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 62 2-3 (2004) 99-118
120. Reeves A.L., So E.L., Sharbrough F.W., and Krahn L.E. Movement disorders associated with the use of gabapentin. Epilepsia 37 (1996) 988-990
121. Reife R., Pledger G., and Wu S.C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41 1 (2000) 66-71
122. Rigo J.-M., Hans G., Nguyen L., Rocher V., Belachew B., Malgrange P., et al. The anti-epileptic drug levetriacetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136 (2002) 659-672
123. Ritter F., Glauser T.A., Elterman R.D., and Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group. Epilepsia 41 1 (2000) 82-85
124. Rogawski M.A. Principles of antiepileptic drug action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs. (5th ed.) (2002), Lippincott Williams & Wilkins, Philadelphia, PA, USA 1-22
125. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 7 (2004) 553-564
126. Rosenfeld W.E., Doose D.R., Walker S.A., and Nayak R.K. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38 (1997) 317-323
127. Rutecki P.A. Noradrenergic modulation of epileptiform activity in the hippocampus. Epilepsy Res 20 (1995) 125-136
128. Sachdeo R.C., Reife R.A., Lim P., and Pledger G. Topiramate monotherapy for partial onset seizures [see comments]. Epilepsia 38 (1997) 294-330
129. Sackellares C.J., Ramsay R.F., and Wilder B.J. Controlled clinical trial of zonisamide: an effective adjunctive treatment for refractory partial seizures. Files of Dainippon Pharmaceutical Co., Ltd. (#912 US) Osaka, Japan (1997)
130. Sadler M. Lamotrigine associated with insomnia. Epilepsia 40 (1999) 322-325
131. Sander J.W. Practical aspects of the use of topiramate in patients with epilepsy. Epilepsia 38 1 (1997) 56-58
132. Schachter S.C. Tiagabine. Epilepsia 40 5 (1999) 17-22
133. Schachter S.C., Vazquez B., Fisher R.S., Laxer K.D., Montouris G.D., Combs C.D., et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures [see comments]. Neurology 52 (1999) 732-737
134. Schachter S.C., Vazquez B., Fisher R.S., Laxer K.D., Combs C.D., Faught E., et al. Oxcarbazepine in a monotherapy trial for partial seizures-placebo-controlled studies in neurology: where do they stop?. Neurology 53 (1999) 2211-2212 (letter)
135. Schapel G.J., Beran R.G., and Vajda F.J. Double-blind placebo-controlled, cross-over study of lamotrigine in treatment resistant partial seizure. J Neurosurg Psychiatry 56 5 (1993) 448-453
136. Schauf C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 413 (1987) 185
137. Schmidt D., Jacob R., and Louiseau P. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 15 (1993) 67-73
138. Schwartzkroin P.A., and Prince D.A. Cellular and field potential properties of epileptogenic hippocampous slices. Brain Res 147 (1978) 117-130
139. 3 pyramidal cells. Science 210 (1980) 1125-1126
140. Shah Y., Shellenberger K., and Canafax D.M. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Zonisamide - Chemistry, Biotransformation, and Pharmacokinetics in Antiepileptic Drugs. (5th ed.). (2002), Lippincott Williams & Wilkins, Philadelphia Section XVII
141. Sharief M., Viteri C., Ben-Menachem E., Weber M., Reife R., Pledger G., et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 25 (1996) 217-222
142. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41 (2000) 1179-1186
143. Shuaib A., Mahmood R.H., Wishart T., Kanthan R., Murabit M.A., Ijaz S., et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res 702 (1995) 199-206
144. Sills G.J., Leach J.P., Fraser C.M., Forrest G., Patsalos P.N., and Brodie M.J. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol 325 (1997) 35-40
145. Silverman R.B., Andruszkiewicz R., Nanavati S.M., Taylor C.P., and Vartanian M.G. 3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase. J Med Chem 34 7 (1991) 2295-2298
146. Stefan H. The challenge: epilepsy treatment. In: Stefan H., Krämer G., and Masmoli B. (Eds). Challenge Epilepsy - New Antiepileptic Drugs (1998), Blackwell Science, Berlin 1-5
147. Stefan H. Epilepsien: Diagnose und Behandlung (1999), Georg Thieme Verlag, Stuttgart
148. Stefan H., Wang-Tilz Y., Pauli E., Genow A., Kerling F., Lorber B., et al. Onset otf action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA). Epilepsia 47 3 (2006) 1-7
149. Stefan H., Lopes da Silva F.H., Löscher W., Schmidt D., Perucca E., Brodie M.J., et al. Epileptogenesis and rational therapeutic strategies. Acta Neurol Scand 113 (2006) 139-155
150. Stefani A., Pisani A., De Murtas M., Mercuri N.B., Marciani M.G., and Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system: II. Modulation of high-voltage-activated calcium currents. Epilepsia 36 10 (1995) 997-1002
151. Stefani A., Spadoni F., and Bernardi G. Differential inhibition by riluzole, lamotrigine and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147 1 (1997) 115-122
152. Stefani A., Spadoni F., and Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 37 (1998) 83-91
153. Stefani A., Hensworth A., Spadoni F., and Bernardi G. The lamotrigine analogue 619 C 89 has been shown to inhibit sodium channels and cloned N typed calcium channels. Br J Pharmacol 125 5 (1998) 1058-1064
154. Steiner T.J., Dellaportas C.I., Findley L.J., Gross M., Gibberd F.B., Pwerkin G.D., et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: double-blind comparison with Phenytoin. Epilepsia 40 5 (1999) 601-607
155. Steinhoff B.J., Hirsch E., Mutani R., and Nakken K.O. The ideal characteristics of antiepileptic therapy: an overview of old and new AEDs. Acta Neurol Scand 107 (2003) 87-95
156. Striano S., Striano P., Bozzella P., Nuzerino C., and Bilo L. Tiagabine in glial tumors. Epilepsy Res 49 (2002) 81-85
157. h in rat CA1 pyramidal cells. Epilepsia 44 2 (2003) 150-156
158. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., et al. Summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29 (1998) 233-249
159. Tecoma E.S. Oxcarbazepine. Epilepsia 40 5 (1999) 37-46
160. Trimble M.R., Rusch N., Betts T., and Crawford P.M. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 9 (2000) 249-254
161. Trojnar M.K., Wojtal K., Trojnar M.P., and Stiripentol C.S.J. A novel antiepileptic drug. Pharmacol Reprod 57 2 (2005) 154-160
162. Turner T.J. Calcium channels coupled to glutamate release. Prog Brain Res 116 (1998) 3-14
163. Uvebrant P., and Bauziene R. Intractable epilepsy in children: the efficacy of lamotrigin treatment including non-seizure related benefit. Neuropediatrics 25 (1994) 284-289
164. Verma A., Miller P., Carwile S.T., Husain A.M., and Radtke R.A. Lamotrigine-induced blepharospasm. Pharmacotherapy 19 (1999) 877-880
165. Wamil A.W., and McLean M.J. Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res 17 (1994) 1-11
166. Wang S.J., Huang C.C., Hsu K.S., Tsai J.J., and Gean P.W. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse 24 (1996) 248-255
167. Wang Y., Zhou D., Wang B., Li H., Chai H., Zhou Q., et al. A kindling model of pharmacoresistant temporal lobe epilepsy in sprague-dawley rats induced by coriaria lactone and its possible mechanism. Epilepsia 44 4 (2003) 475-488
168. 3H-Stiripentol. Cell Mol Biol Incl Cyto Enzymol 24 1 (1997) 51-60
169. White H.S., Brown S.D., Woofhead J.H., Skeen G.A., and Wolf H.H. Topiramate modulates GABA evoked currents in murine cortical neurons by a non-benzodiazepine mechnism. Epilepsia 41 1 (2000) 17-20
170. Wickenden A.D. Potassium channels as anti-epileptic drug targets. Neuropharmacology 43 7 (2002) 1055-1060
171. Wong R.K., and Prince D.A. Dendritic mechanisms underlying penicillininduced epileptiform activity. Science 204 (1979) 1228-1231
172. Yagi K., and Seino M. Open clinical trial of new antiepileptic drug, zonisaminde (ZNA) on 49 patients with refractory epileptic seizure. Clin Psychiatry 29 (1992) 111-119
173. Yan Q.S., Mishra P.K., Burger R.L., Bettendorf A.F., Jobe P.C., and Dailey J.W. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther 261 2 (1992) 652-659
174. Yoshida S., Okada M., Zhu G., and Kaneko S. Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Res 67 3 (2005) 153-162
175. Zaccara G., Gangemi P.F., Bendoni L., Menge G.P., Schwabe S., and Monza G.C. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 15 (1993) 39-42
176. Zipp F., Baas H., and Fischer P.A. Lamotrigine-antiparkinsonian activity by blockade of glutamate release?. J Neural Transm Parkinsons Dis Dement Sect 5 (1993) 67-75
177. Zona C., Ciotti M.T., and Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 231 (1997) 123-126